Download by
Scanning QR Code
No Data
US Stock MarketDetailed Quotes
AKTX Akari Therapeutics
Watchlist
3.7000
+0.0877+2.43% Trading 10/03 15:28 ET
3.7573High3.6988Low2.70KVolume
3.6988Open3.6123Pre Close10.07KTurnover0.10%Turnover RatioLossP/E (TTM)18.71MMarket Cap12.546052wk HighLossP/E (Static)5.06MShares2.808052wk Low10.28P/B10.44MFloat Cap5000.0000Historical High--Dividend TTM2.82MShs Float2.8000Historical Low--Div YieldTTM1.62%Amplitude3.7220Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Akari Therapeutics Company
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
News
European Equities Traded in the US as American Depositary Receipts Fall Sharply Lower Monday
European equities traded in the US as American depositary receipts fell sharply to open the week on a down note Monday, as they fell 1.57% to 1,170.06 on the S&P Europe Select ADR Index. From continen
Akari Therapeutics GAAP EPS of $0.00
Akari Therapeutics H1 2023 Net Loss Of $2.99M Versus $10.8M A Year Ago, Cash Balance Of Approximately $7.2M Sufficient To Fund Operations Into Q1 Of 2024
Akari Therapeutics (NASDAQ:AKTX) will report on H1 2023.